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ABSTRACT
Fungal infections are among the most serious infectious complications in immunosuppressed patients. Pri-
mary cutaneous aspergillosis is a relatively rare manifestation and is usually described in patients with un-
derlying malignant hematological diseases, AIDS, allogenic stem cell transplantation, solid organ trans-
plantation, etc. We present a clinical case of a 12-year-old boy with acute lymphoblastic leukemia initial-
ly diagnosed as primary cutaneous aspergillosis caused by Aspergillus flavus. The retrospective analysis 
demonstrates that a small solitary pulmonary nodule could be a possible portal of entry. This means that 
we could consider the disease as an early stage invasive aspergillosis, which is successfully treated with vori-
conazole.
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INTRODUCTION 
Fungi belonging to the genus Aspergillus are 
typical opportunistic pathogens. Due to airborne 
contamination the lungs and sinuses are the most 
common primary sites of infection, although Asper-
gillus can disseminate to distant organs and manifest 
as invasive aspergillosis (IA). Primary cutaneous le-
sions as a result of direct implantation of Aspergillus 
spores can occur in some cases and are usually devel-
oped after skin barrier disruption (1).  Primary cuta-
neous aspergillosis (PCA) in immunocompromised 
patients has the potential to progress to systemic in-
fection and is frequently lethal (1,2). An adequate and 
rapid microbiological diagnosis is of essential impor-
tance for the prompt therapy of these patients.  Here 
we present a clinical case of a 12-year-old boy ini-
tially diagnosed with PCA, successfully treated with 
voriconazole. Later the disease was defined as an ear-
ly stage of IA.
CASE DESCRIPTION 
A 12-year-old patient presented with a low-
grade fever, weakness, bone and joint pain, lymph-
adenopathy, hepatosplenomegaly and WBC 178 
x109 per liter.  Bone marrow aspirate smears re-
vealed 100% infiltration with lymphoblasts. Diag-
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The response was poor on D8 and remission was not 
achieved at the end of the induction on D33.
While the patient was neutropenic, a small skin 
lesion was noticed on the back side of the patient’s 
right hip. The lesion progressed into weakly painful 
ulcerative papule with a size of approximately 8 mm 
with central necrosis, surrounded by a zone of local 
hyperemia (Fig. 1A). A skin biopsy sample was col-
lected and cultured on Sabouraud agar at 30°C and 
after 48 hours mold colonies with yellow-green pig-
mentation were found (Fig. 1B). Microscopic exami-
nation of colonies revealed the typical morphologi-
cal characteristics of Aspergillus flavus. Histopatho-
logical examination of the skin biopsy sample dem-
onstrated adipose tissue with inflammatory cells and 
necrotic zones, numerous branched dichotomous at 
45° angles septate hyphae and conidiospores sugges-
tive for Aspergillus spp. (Fig. 1C).
Computed tomography (CT) scanning of the 
chest was done twice and revealed normal lung pa-
renchyma with a single small nodular lesion and no 
other typical for invasive pulmonary aspergillosis 
(IPA) signs (cavitation, halo sign, etc.) (Fig. 2). Serum 
levels of galactomannan were tested twice and both 
results were negative. 
Antifungal therapy with voriconazole was ini-
tiated with 600 mg/d on the first day, and then 400 
mg/d. The second lung CT performed after 6 weeks 
nosis of high-risk T-cell acute lymphoblastic anemia 
with central nervous system (CNS) involvement was 
made and course of chemotherapy according to the 
phase 1 of ALL IC BFM 2009 Protocol was started. 
Fig. 1. Cutaneous aspergillosis. A. The initial presentation 
of described in text skin lesion. B. Colonies of Aspergillus 
flavus after 48 hours of incubation on Sabouraud agar. C. 
Microphotography of the skin biopsy sample demonstrates 
necrotic zones, with numerous branched hyphae and co-
nidiospores suggestive of Aspergillus species.
Fig. 2. CT scan before the start of antifungal therapy. A and B. CT scan demonstrates a solitary nodule of <1cm in diam-
eter in the upper lobe of the left lung.
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of antifungal treatment was clear: the solitary nodule 
in the left lung disappeared and new lesions were not 
found. The skin lesion decreased in size and com-
pletely disappeared in 5 weeks. The patient contin-
ued to get chemotherapy and at present is in prepa-
ration to receive allogeneic haematopoietic stem cell 
transplantation from a matched unrelated donor.
DISCUSSION 
Aspergillosis in immunocompromized patients 
is one of the most worrisome infectious complica-
tions. It is often described in patients with hematho-
logical malignancies and in most cases presents as 
IA. Cutaneous aspergillosis, both primary and sec-
ondary to hematogenous dissemination of Aspergil-
lus spp.  is a relatively rare clinical manifestation.
An ulcerative necrotic skin lesion in a patient 
on chemotherapy is a frequent finding but usual-
ly a solitary, non-disturbing lesion without symp-
toms of generalized infection can be easily omitted. 
The place of fungal infection in such lesions is not 
dominant. A standard monitoring with Aspergillus 
galactomannan antigen test is useful in certain cir-
cumstances but its sensitivity varies between 52.9 % 
and 79.3% (3) and cannot fully substitute the clinical 
examination. 
PCA is an uncommon disease, mostly de-
scribed in case reports (4-7). It typically develops on 
the place of disruption of skin integrity. This was not 
the case in the described patient, which makes it es-
pecially unusual for PCA. 
Viewed in this way, a single small lung lesion 
detected on CT examination can be of special inter-
est. This incidental finding is difficult to interpret. A 
solitary pulmonary nodule can be caused by a range 
of conditions varying from an infection or other be-
nign lesion to a malignancy. Meanwhile, with im-
proved imaging technique more nodules can be de-
tected, but the explanation of the presence of solitary 
lesions remains unclear (8). 
In neutropenic patients with leukemia the in-
cidence of IA exceeds 4-5% (9-11). The typical ear-
ly findings in IPA are ≥1 macronodules often with a 
“halo sign”. Small solitary lesions (<1 cm) might be 
present in only a small percent of all patients with 
IPA (12). Indeed, if similar nodule is found on CT 
scan as part of a disseminated  pulmonary process it 
would be taken as a part of the same infection, while 
just a solitary lesion is more likely to be interpreted 
as “non-specific”.
In the present case, considering the proven skin 
aspergillosis, and disappearance of the lung lesion af-
ter specific therapy there is enough proof that both 
lesions belong to the same process and we have good 
reason to define the disease as IA. 
After not finding any other focus of infection, 
the question which of these two loci is primary: the 
skin (proven) or the lung (probable) was raised.  
We proved that the skin lesion was caused by 
A. flavus. A retrospective study on deep cutaneous 
fungal infections in immunocompromised children 
showed that Aspergillus spp. was the most common 
pathogen, responsible for 44% of the cases. In this 
study Aspergillus flavus was the most commonly iso-
lated species (14). 
Only relatively small conidia are able to evade 
the pulmonary clearance. A. fumigatus conidia are 
smaller in size than those of A. flavus. As a result 
A. fumigatus has a dominant role in IPA. Currently 
some data shows a growing frequency of other non-
Aspergillus fumigatus species (15-17). 
In PCA cases, which develop due to direct fun-
gal inoculation, the size of conidia does not play a sig-
nificant role. But in addition to the size of the spores 
there are numerous factors, like surface characteris-
tics, pigment composition, adhesion properties, re-
sistance to phagocytosis, resistance to temperature 
and other environmental conditions, such as weath-
er, etc., which influence the epidemiology, the way 
of clinical presentation e.g. preferable localization of 
primary invasion  (14). This data demonstrates high-
er virulence of A. flavus than A. fumigatus. There-
fore A. flavus, as a causative agent in our case, does 
not exclude primary invasion via lungs followed by 
rapid hematogenous dissemination to the skin which 
was the evident presentation in this patient. If a small 
skin lesion is missed, another, less favorable scenar-
io could developed: disseminated bulky lung impair-
ment and different end organ involvement, e.g. CNS. 
Such evolution would be more resistant to treatment 
and would have significantly worse prognosis.
Voriconazole belongs to the group of mold–ac-
tive second generation azoles. It is approved for first-
line treatment of IA and for cutaneous aspergillosis 
(18). Despite the fact that resistance to azoles in As-
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pergillus spp. has already been reported, most studies 
show that the activity of voriconazole remains excel-
lent (19,20).  In this case voriconazole demonstrated 
a full effect and the antileukemic program was not 
modified.
In conclusion, this “simple” case demonstrates 
that cutaneous aspergillosis may occur in immuno-
suppressed patients as part of probable invasive as-
pergillosis. The case shows that serial gallactoman-
nan antigen evaluations do not substitute repeated 
lung CT scanning for monitoring for invasive fun-
gal infection. The correct and rapid microbiological 
diagnosis and early start of specific treatment with 
proper antifungal agent is the key to a successful out-
come in high-risk patients.
REFERENCES
1. Van Burik JA , Colven R, Spach DH. Cutaneous as-
pergillosis. J Clin Microbiol. 1998;36(11):3115–21.
2. Walsh TJ. Primary cutaneous aspergillosis—an 
emerging infection among immunocompromised 
patients. Clin Infect Dis . 1998;27(3):453–7.
3. Ascioglu S, Rex JH, De Pauw B, Bennett JE, Bille J, 
Crokaert F, et al. Defining opportunistic invasive 
fungal infections in immunocompromised patients 
with cancer and hematopoietic stem cell trans-
plants: an international consensus. Clin Infect Dis. 
2002, 34(1):7-14. doi: 10.1086/323335.
4. Dal T, Tekin A, Tekin R, Deveci Ö, Fırat U, Mete 
M, et al. Soft tissue abscess caused by Aspergillus 
fumigatus in an immunosuppressive patient. Eur J 
Gen Med. 2013;10:118-122.
5. Saghrouni F, Gheith S, Yaacoub A, Ammous O, 
Ben Abdeljelil J, Fathallah A, et al. Primary cutane-
ous aspergillosis due to Aspergillus flavus in a neu-
tropenic patient. J Mycol Med. 2011; 21(4):285—8. 
doi: 10.1016/j.mycmed.2011.09.003.
6. Torrelo A, Hernández-Martín A, Scaglione,C 
Madero L, Colmenero I, Zambrano A. Primary cu-
taneous cspergillosis in a leukemic child. Actas 
Dermosifiliogr. 2007;98(4):276-8.
7. Darr-Foit S, Schliemann S, Scholl S, Hipler UC, El-
sner P. Primary cutaneous aspergillosis - an un-
common opportunistic infection Review of the lit-
erature and case presentation. J Dtsch Dermatol 
Ges. 2017;15(8):839-41. doi: 10.1111/ddg.13297. 
8. Wahidi MM, Govert JA, Goudar RK, Gould MK, 
McCrory DC, American College of Chest Physi-
cians. Evidence for the treatment of patients with 
pulmonary nodules: when is it lung cancer?: ACCP 
evidence-based clinical practice guidelines (2nd 
edition). Chest. 2007;132(Suppl 3):94-107. doi: 
10.1378/chest.07-1352.
9. Zaoutis TE, Heydon K, Chu JH, Walsh TJ, Stein-
bach WJ. Epidemiology, outcomes, and costs of 
invasive aspergillosis in immunocompromised 
children in the United States, 2000. Pediatrics. 
2006;117(4):711-16. doi: 10.1542/peds.2005-1161.
10. Crassard N, Hadden H, Piens MA, Pondarré C, 
Hadden R, Galambrun C, et al. Invasive asper-
gillosis in a paediatric haematology department: 
a 15-year review. Mycoses. 2008;51(2):109-16.doi: 
10.1111/j.1439-0507.2007.01449.x.  
11. Steinbach WJ. Invasive aspergillosis in pediatric 
patients. Curr Med Res Opin. 2010; 26(7):1779-87.
doi: 10.1185/03007995.2010.487793.
12. Greene RE, Schlamm HT, Oestmann JW, Stark P, 
Durand C, Lortholary O, et al. Imaging findings 
in acute invasive pulmonary aspergillosis: clini-
cal significance of the halo sign. Clin Infect Dis. 
2007;44(3):373-9. doi: 10.1086/509917.
13. Marcoux D, Jafarian F, Joncas V, Buteau C, Kok-
ta V, Moghrabi A. Deep cutaneous fungal infec-
tions in immunocompromised children. J Am 
Acad Dermatol. 2009;61(5):857-64. doi: 10.1016/j.
jaad.2009.02.052.
14. Pasqualotto AC. Differences in pathogenicity and 
clinical syndromes due to Aspergillus fumigatus 
and Aspergillus flavus. Med Mycol. 2009;47(Suppl 
1): 261-70. doi: 10.1080/13693780802247702.
15. Lass-Flörl C, Griff K, Mayr A, Petzer A, Gastl G, 
Bonatti H, et al. Epidemiology and outcome of in-
fections due to Aspergillus terreus: 10-year single 
centre experience. Br J Haematol. 2005;131(2):201-7. 
doi: 10.1111/j.1365-2141.2005.05763.x.
16. Mayr A, Lass-Flörl C. Epidemiology and antifun-
gal resistance in invasive Aspergillosis according to 
primary disease: review of the literature. Eur J Med 
Res. 2011;16(4):153-7. 
17. Marr KA, Carter RA, Crippa F, Wald A, Corey L. 
Epidemiology and outcome of mould infections in 
hematopoietic stem cell transplant recipients. Clin 
Infect Dis. 2002;34(7):909-17. doi: 10.1086/339202.
18. Patterson TF, Thompson GR 3rd, Denning 
DW, Fishman JA, Hadley S, Herbrecht R.  Prac-
tice Guidelines for the Diagnosis and Manage-
ment of Aspergillosis: 2016 Update by the Infec-
46 Scripta Scientifica Medica, 2018;50(2):42-46Medical University of Varna
  Cutaneous Aspergillosis in a Boy with Acute Leukemia: The Lessons from a “Simple” Case
tious Diseases Society of America. Clin Infect Dis. 
2016;63(4):433-42. doi: 10.1093/cid/ciw444. 
19. Snelders E, Van der Lee HA, Kuijpers J, Rijs AJ, 
Varga J, Samson RA, et al. Emergence of azole re-
sistance in Aspergillus fumigatus and spread 
of a single resistance mechanism. PLoS Med. 
2008;5(11):e219. doi: 10.1371/journal.pmed.0050219. 
20. Koehler P, Hamprecht A, Bader O, Bekeredjian-
Ding I, Buchheidt D, Doelken G, et al . Epidemi-
ology of invasive aspergillosis and azole resistance 
in patients with acute leukaemia: the SEPIA Study. 
Int J Antimicrob Agents. 2017;49(2):218-223. doi: 
10.1016/j.ijantimicag.2016.10.019. 
